Everything you need to know about the coronavirus vaccine race

Here are your answers to the questions that matter the most about COVID-19 vaccines in development

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

COVID-19 cases and deaths continue to rise in the United States. Some states are being hit especially hard. While researchers and physicians have learned a lot about the disease caused by novel coronavirus SARS-CoV-2, there seems to be no end in sight to the ongoing pandemic.

The good news, though, is that a frantic – and massive – effort is under way to develop vaccines that could potentially prevent the spread of COVID-19. Here's everything you need to know about the coronavirus vaccine race.

How many vaccine candidates are being developed?

As of July 31, 2020, there are 165 novel coronavirus vaccine candidates in development, according to the World Health Organization. However, 139 of these candidates are in preclinical testing. Many of these candidates might not advance into clinical testing in humans. The good news is that 26 COVID-19 vaccine candidates are already in clinical testing. 

Which vaccine candidates are in the lead?

Clinical testing of vaccines includes three phases. Candidates must successfully complete phase 1 testing to go on to phase 2 and then must successfully complete phase 2 testing to advance into phase 3.

There are currently five COVID-19 vaccine candidates in phase 3 testing, also commonly referred to as late-stage testing. Chinese drugmaker Sinopharm claims two of these candidates. Another Chinese company, Sinovac Biotech, also has a COVID-19 vaccine candidate in phase 3 testing. The other two late-stage candidates are AZD1222, which is being developed by AstraZeneca (NYSE: AZN) and the University of Oxford, and Moderna's (NASDAQ: MRNA) mRNA-1273.

In addition, Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) recently began a phase 2/3 clinical study evaluating COVID-19 vaccine candidate BNT162b2.

How do the leading vaccine candidates differ?

The vaccine candidates from Sinopharm and Sinovac use inactivated (dead) coronavirus cells that are introduced to the body. AstraZeneca and the University of Oxford are using what's called a non-replicating viral vector. This approach uses a weakened version of an adenovirus (which causes the common cold) to deliver genetic material from the SARS-CoV-2 virus. 

Moderna and the Pfizer/BioNTech partnership use a messenger RNA (mRNA) approach. While DNA contains all of the instructions for building proteins, mRNA carries those instructions to ribosomes, which serve as the body's protein-making factories. The COVID-19 vaccine candidates developed by Moderna and Pfizer/BioNTech modify mRNA to cause ribosomes to produce spike proteins that are identical to those found in SARS-CoV-2.

The ultimate goal of all of these vaccines is to cause the body to develop antigens that remain in the blood and help fight off future viral attacks. 

Which vaccines not among the leaders could be winners?

Two COVID-19 vaccine candidates currently in clinical testing have received significant funding and appear to be especially promising. 

Novavax (NASDAQ: NVAX) received $1.6 billion from the U.S. government for developing COVID-19 vaccine candidate NVX-CoV2373. Johnson & Johnson (NYSE: JNJ) also was awarded $456 million in funding for its coronavirus vaccine candidate. 

There's also an experimental COVID-19 vaccine that hasn't advanced into clinical testing that scored a major U.S. government funding deal recently. Sanofi (NASDAQ: SNY) and GlaxoSmithKline (NYSE: GSK) were awarded $2.1 billion for up to 100 million doses of a preclinical coronavirus vaccine candidate. 

How soon might a vaccine be available?

In the past, it's taken years for vaccines to advance through clinical testing and win regulatory approvals. However, the normal timeline is being accelerated greatly as a result of the COVID-19 pandemic.

Opinions vary as to how soon a coronavirus vaccine will be available. Some CEOs of companies making vaccine candidates think their COVID-19 vaccine candidates could be ready by the end of this year. Others believe that early 2021 is more likely. However, there are also some less optimistic predictions that it could take much longer before a safe and effective COVID-19 vaccine is ready.

What are the chances that no vaccine will be safe and effective?

You'll probably be happy to learn that the chances that none of the COVID-19 vaccine candidates in development will be safe and effective are quite low. Nearly three out of four vaccines that entered phase 3 testing between 2006 and 2015 went on to win FDA approval, according to biopharmaceutical industry organization BIO. 

Since there are currently six coronavirus vaccine candidates in late-stage testing or close to it, the probability that none of them will win approval based on BIO's historical analysis is only one in 3,470. If we included all of the other candidates in phase 1 and phase 2 clinical testing, the odds are heavily in favor of at least one of them achieving success.

Which coronavirus vaccine stocks are good picks?

The Motley Fool's mission is to make the world smarter, happier, and richer. Therefore, we can't leave out addressing the investing angle of the coronavirus vaccine race. 

If your investing style is more conservative, big pharma stocks like AstraZeneca and Pfizer could be attractive. Both companies are leaders in the scramble to develop a COVID-19 vaccine. Both have landed major supply contracts already. And both AstraZeneca and Pfizer have other growth drivers in addition to their COVID-19 programs.

On the other hand, if you're an aggressive investor, Moderna and Novavax might be more to your liking. Both biotech stocks have soared this year. But if their COVID-19 vaccine candidates are successful in clinical testing, Moderna and Novavax could go a lot higher.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Keith Speights owns shares of Pfizer. The Motley Fool Australia's parent company Motley Fool Holdings Inc. recommends Johnson & Johnson. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on International Stock News

US economy and sharemarket with piggy bank
International Stock News

What on earth is going on with the US stock market?

Let's dive in and see.

Read more »

A graphic illustration with the words NASDAQ atop a US city and currency
International Stock News

Why Big Tech became a huge wreck across the Nasdaq last night

Jerome Powell and his compadres shocked the market with an unexpected outlook.

Read more »

a man sits at a bar leaning sadly on his basketball wearing a US flag sticker on his cheekbone near a half drunk beer and looking despondent as though his basketball team has just lost a game.
International Stock News

The Dow Jones is on its longest losing streak in 46 years. What's going on?

The Dow is on a losing streak in the middle of a boom.

Read more »

A person leans over to whisper a secret to a colleague during a meeting.
International Stock News

Despite recent news, analysts still say Nvidia stock is a buy. Here's why

Last month, Nvidia was the most valuable company in the world.

Read more »

A young girl looks up and balances a pencil on her nose, while thinking about a decision she has to make.
International Stock News

After gaining 2,100%, is Nvidia stock done?

Nvidia has taken off as one of the key players in chips and services for artificial intelligence.

Read more »

A young couple in the back of a convertible car each raise a single arm in the air whilst enjoying a drive along the road.
International Stock News

Why Tesla stock just jumped again

Wedbush's Dan Ives thinks the stock will keep moving higher thanks to Tesla's self-driving technology.

Read more »

An older couple hold hands as they bounce happily high in the air.
International Stock News

Why the Alphabet share price just leapt higher

Investors seem to hope the Trump administration will be friendly to Alphabet and its big-tech peers.

Read more »

A panel of four judges hold up cards all showing the perfect score of ten out of ten
International Stock News

Top Wall Street analyst calls Tesla stock a top pick. Is it a buy now?

Tesla shares have been on fire lately, rising more than 70% since the November 5 election.

Read more »